Basic scienceImmunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate☆
Section snippets
Material and methods
We investigated 40 prostate cancer cases comprised of 31 radical prostatectomy specimens obtained from patients with clinically organ-confined prostate cancer and 9 prostate needle biopsy specimens from patients with bone metastasis. In addition, 8 noncancerous prostatic specimens, including 3 subcapsular prostatectomy specimens from patients with benign prostatic hyperplasia (BPH) and 5 prostates without prostatic diseases obtained from young autopsy cases, were studied. All samples were
Results
In prostate cancer cases, PD-ECGF was expressed in the stromal cells within cancer tissues in 32 (80%) of the 40 cases (Fig. 1A,B). There were no differences in the intensity of PD-ECGF expression between cancer tissues with scant stroma and those with abundant stroma. The PD-ECGF-positive stromal cells consisted of fibroblasts, lymphocytes, macrophages, endothelial cells, smooth muscle cells, and Schwann cells (Table I). However, cancer cells were almost negative for PD-ECGF (Fig. 1A,B). The
Comment
Our results showed that PD-ECGF was expressed in the stromal cells within cancer tissues, including fibroblasts, lymphocytes, macrophages, endothelial cells, smooth muscle cells, and Schwann cells, in 80% of the 40 prostate cancer cases. However, almost all of the prostate cancer cells had negative expression of PD-ECGF. It has been reported in breast,21 colon,22 and lung cancers23 that noncancerous stromal cells, in addition to cancer cells, express PD-ECGF. Takahashi et al.,24 however,
Conclusions
In this study, we concluded that expression of PD-ECGF in the stromal cells within cancer tissues was significantly associated with tumor vascularity and that it might play an important role in tumor angiogenesis and distant metastasis in prostate cancer.
Acknowledgements
To Nippon Roche Co. Ltd. for kindly providing the antibody against PD-ECGF, 654-1.
References (29)
- et al.
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
J Urol
(1998) - et al.
Vascular endothelial growth factor (VEGF) expression in human prostate cancerin situ and in vitro expression of VEGF by human prostate cancer cells
J Urol
(1997) - et al.
Purification and properties of an endothelial cell growth factor from human platelets
J Biol Chem
(1987) - et al.
Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostatelack of significance for microvessel density analysis
Urology
(1998) - et al.
Interactions of interferon-α2a with 5′-deoxy-5-fluorouridine in colorectal cancer cells in vitro
Eur J Cancer
(1992) What is the evidence that tumors are angiogenesis dependent?
J Natl Cancer Inst
(1990)- et al.
Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma
N Engl J Med
(1991) - et al.
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
Cancer Res
(1995) - et al.
Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
Br J Urol
(1994) - et al.
Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
Cancer Res
(1994)
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
Am J Pathol
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
Cancer
Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
Prostate
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma
Am J Pathol
Cited by (22)
Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy
2007, Biochemical PharmacologyAngiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches
2002, Molecular and Cellular EndocrinologyScoping Review on Platelets and Tumor Angiogenesis: Do We Need More Evidence or Better Analysis?
2022, International Journal of Molecular SciencesThe metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer
2012, Cancer Biology and TherapyMyocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats
2010, Biochemistry and Cell Biology
- ☆
Partially supported by a Grant-in-Aid (No. 11770096) for Encouragement of Young Scientists from the Ministry of Education, Science, and Culture of Japan.